US sues PharMerica over drug dispensing, Medicare fraud – Chicago Tribune (blog)

See on Scoop.it – Medicare and Medicaid Whistleblower Rights US sues PharMerica over drug dispensing, Medicare fraud Chicago Tribune (blog) According to the complaint, PharMerica between 2007 and 2009 dispensed controlled drugs several thousand times without first getting valid written prescriptions from… See on...

read more

Medicare Whistleblower Pharmacy Receives Millions

A Medicare whistleblower pharmacy in Florida is leading the way in reporting Medicare fraud.  After numerous successful False Claims Act cases, Ven-a-care pharmacy is making millions in Medicare fraud rewards. Reporting Medicare Fraud in Florida A special report from Florida Trend details how the small pharmacy has become one of the most successful Medicare whistleblowers in the country.  Ven-a-care is responsible for exposing billions in over-charges to Medicare and Medicaid for prescription drugs. Explains the report: In August 2011, Attorney General Pam Bondi filed a three-paragraph...

read more

$17M Off-Label Marketing Whistleblower Reward

A whistleblower in an off-label marketing case against Boehringer Ingelheim Pharmaceuticals Inc. will receive more than $17 million as a reward.  The reward is his share of a $95 million settlement with the government.  Whistleblowers get a share of such settlements as a reward for reporting fraud under the False Claims Act. Robert Heiden, a former sales representative for Boehringer, blew the whistle on the company’s illegal off-label marketing of three different drugs.  The three drugs were Aggrenox, Combivent, and Micardis. The government alleged that Boehreinger marketed these...

read more

Abbott Labs Fined $700M for Off Label Marketing

For off label marketing of the drug Depakote, a federal district judge last week ordered Abbott Laboratories to pay a $500 Million criminal fine, to forfeit $198.5 Million, and to pay $1.5 Million to the Virginia Medicaid Fraud Control Unit. In May, Abbott Laboratories pled guilty to off-label marketing of Depakote for dementia and schizophrenia, uses not approved by the FDA.  It also settled allegations that it marketed Depakote for psychiatric illnesses in children, including conduct disorders, attention deficit disorder and autism, and other psychiatric illnesses in adults, including...

read more

Off-label Drug Marketing of Antipsychotic Drugs for Children?

A new study found a 62% increase in the number of children ages 3 to 18 who are enrolled in Medicaid taking antipsychotic drugs in the last ten years.  The number of children taking such antipsychotics was 354,000 in 2007.  Science Daily reports: Increased antipsychotic use was observed across a wide range of mental health diagnoses, and was particularly high for children with ADHD or conduct disorder, although the FDA has not approved the drugs to treat these conditions in children. In total, 65% of children prescribed antipsychotics in 2007 were using the drugs “off-label,” or...

read more

GlaxoSmithKline to Pay $3 Billion in Pharmaceutical Whistleblower Case

Pharmaceutical company GlaxoSmithKline has agreed to pay $3 billion in fines to the government in a pharmaceutical whistleblower case.  This is the largest pharmaceutical fraud settlement to date, and brings whistleblower lawsuit settlements to a total of $10 billion for 2012.  Whistleblowers get a share of these settlements as a reward for reporting fraud under the False Claims Act. The pharmaceutical whistleblowers were four GSK employees, including a vice president and a senior marketing development manager.  The pharmaceutical fraud involved GSK’s conduct regarding Paxil,...

read more

Facebook